We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene Uncovered Associated with Aggressive Breast Cancer

By LabMedica International staff writers
Posted on 14 Dec 2014
A biomarker has been identified that is strongly associated with triple negative breast cancer (TNBC), a highly aggressive carcinoma that often has early relapse and metastasis following chemotherapy. More...


TNBC is characterized by tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2), and represents the most aggressive subtype of breast cancer, with a high rate of relapse and no available therapeutic targets.

Scientists at the A*STAR Genome Institute (Singapore) used quantitative polymerase chain reaction (qPCR) and western blotting for micro ribonucleic acid (miRNA) profiling of breast cancer cells and quantitative real-time PCR for validation. Total RNAs were isolated and purified with the miRNeasy Mini Kit (Qiagen; Venlo, The Netherlands). The miRNA expression array hybridization was performed using the Human miRNA Microarray Kit V3 (Agilent, Santa Clara, CA, USA), and data analysis was performed. Immunohistochemistry was also implemented.

The team found that small RNA, often called microRNA, is lost in highly metastatic TNBC cells but not in luminal breast cancer. As a result, the gene RAS Protein Activator Like 2 (RASAL2), which is negatively regulated by this microRNA, is upregulated in a set of TNBC tumors. The study showed that TNBC patients whose tumors have high expression of RASAL2 tend to have a lower survival rate as compared to patients whose tumors have low levels of this gene. Additionally, the study showed that genetic knockdown of RASAL2 gene can lead to reduced metastasis in breast cancer mouse model.

Qiang Yu, PhD, a professor and project leader of the study, said, “Cancer is an extremely heterogeneous disease, where many molecular processes have gone wrong in their own ways. Rather than a tumor suppressor, we show here that RASAL2 actually acts as a cancer promoting molecule in TNBC. This reminds us that the same molecule can function very differently in different subtypes of cancers, a phenomenon which has often been seen before.” The study was published on November 10, 2014, in the Journal of Clinical Investigation.

Related Links:

A*STAR Genome Institute
Qiagen 
Agilent 



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Platelet Function Analyzer
PL-12
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.